EWTX 250117 22.50C (EWTX250117C22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

EWTX250117C22500

Watchlist

9.50
0.000.00%

15min DelayTrading Dec 20 10:06 ET

0.00High0.00Low

Intraday

5D
Daily

News

Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $50
BenzingaDec 17 10:43 ET · Ratings
Edgewise Therapeutics Analyst Ratings
BenzingaDec 17 10:41 ET · Ratings
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
Moomoo NewsDec 17 09:34 ET · Ratings
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
Zacks Dec 17 08:30 ET
A Quick Look at Today's Ratings for Edgewise Therapeutics(EWTX.US), With a Forecast Between $50 to $50
Moomoo NewsDec 17 08:00 ET · Ratings
Edgewise Therapeutics Price Target Raised to $50 From $44 at Leerink
TipRanksDec 16 15:50 ET

Comments

Jaguar8

Dec 16 05:10

NEWS

$Edgewise Therapeutics (EWTX.US)$
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
– Trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date –
– On the key secondary endpoint, sevasemten-treated patients showed stabilization of North Star Ambulatory Assess...

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Jaguar8

Apr 15 15:07

$Edgewise Therapeutics (EWTX.US)$
NEWS
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Positive two-year topline results from the ARCH trial show stabilization of NSAA scores with sevasemten treatment in adults with Becker Muscular Dystrophy.
Significant decreases in muscle damage biomarkers CK and TNNI2 were observed in participants treated with sevasemten.
Sevasemten was...